Privia Health Group Inc (PRVA)
Official siteHEALTHCARE • HEALTH INFORMATION SERVICES • NASDAQ
Market Cap: $3.14B
Last updated: Nov 17, 2026 at 11:06 AM ET
Privia Health Group Inc (PRVA) Earnings: Report Dates and Results
Privia Health Group (PRVA) is expected to report earnings on Feb 24, 2027. In the quarter ended Sep 30, 2026, Privia Health Group reported EPS of $0.10, above the $0.09 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
PRVA has an expected report date of Feb 24, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 71.4% above the $0.07 reported for the quarter ended Dec 31, 2025.
PRVA Earnings Call
The latest PRVA earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 24 quarters below that had an estimate, PRVA beat 18, missed 5 and matched 1. Revenue for the quarter ended Sep 30, 2026 was $656.96M, up 13.2% from $580.42M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.10 | $0.09 | N/A | +11.11% | Beat | -65.5% | 10 | 5 up, 4 down | Nov 5, 2026 | $656.96M |
| Jun 30, 2026 | $0.07 | $0.08 | N/A | -12.50% | Miss | +250.0% | 11 | 2 up, 7 down | Aug 6, 2026 | $632.63M |
| Mar 31, 2026 | $0.19 | $0.25 | $0.19 - $0.28 | -24.00% | Miss | -13.6% | 11 | 1 up, 1 down | May 7, 2026 | $603.85M |
| Dec 31, 2025 | $0.07 | $0.04 | N/A | +75.00% | Beat | -66.7% | 12 | 1 up, 1 down | Feb 26, 2026 | $541.17M |
| Sep 30, 2025 | $0.29 | $0.22 | $0.17 - $0.24 | +31.82% | Beat | +45.0% | 10 | 2 up, 1 down | Nov 6, 2025 | $580.42M |
| Jun 30, 2025 | $0.02 | $0.05 | N/A | -60.00% | Miss | -89.5% | 12 | 3 up, 4 down | Aug 7, 2025 | $521.15M |
| Mar 31, 2025 | $0.22 | $0.18 | $0.12 - $0.22 | +22.22% | Beat | +22.2% | 12 | 3 up, 4 down | May 8, 2025 | $480.10M |
| Dec 31, 2024 | $0.21 | $0.20 | $0.15 - $0.22 | +4.58% | Beat | +950.0% | 12 | 0 up, 1 down | Feb 27, 2025 | $460.90M |
| Sep 30, 2024 | $0.20 | $0.20 | N/A | 0.00% | In line | +17.6% | 15 | 0 up, 1 down | Nov 7, 2024 | $437.92M |
| Jun 30, 2024 | $0.19 | $0.18 | N/A | +5.56% | Beat | +11.8% | 13 | 1 up, 1 down | Aug 8, 2024 | $422.33M |
| Mar 31, 2024 | $0.18 | $0.15 | N/A | +20.00% | Beat | +12.5% | 14 | 1 up, 0 down | May 9, 2024 | $415.24M |
| Dec 31, 2023 | $0.02 | $0.04 | $0.00 - $0.07 | -50.00% | Miss | -85.7% | 13 | 0 up, 2 down | Feb 27, 2024 | $440.83M |
| Sep 30, 2023 | $0.17 | $0.16 | N/A | +6.25% | Beat | +30.8% | 12 | 0 up, 0 down | Nov 3, 2023 | $417.28M |
| Jun 30, 2023 | $0.17 | $0.14 | N/A | +21.43% | Beat | +30.8% | 13 | 0 up, 0 down | Aug 3, 2023 | $413.35M |
| Mar 31, 2023 | $0.16 | $0.14 | N/A | +14.29% | Beat | +33.3% | 12 | 0 up, 0 down | May 4, 2023 | $386.28M |
| Dec 31, 2022 | $0.14 | -$0.03 | -$0.06 - $0.01 | +566.67% | Beat | N/A | 11 | 0 up, 0 down | Feb 28, 2023 | $364.42M |
| Sep 30, 2022 | $0.13 | $0.12 | N/A | +8.33% | Beat | N/A | 9 | 0 up, 0 down | Nov 10, 2022 | $342.90M |
| Jun 30, 2022 | $0.13 | $0.10 | N/A | +30.00% | Beat | N/A | N/A | 1 up, 0 down | Aug 11, 2022 | $335.54M |
| Mar 31, 2022 | $0.12 | $0.09 | N/A | +33.33% | Beat | +100.0% | 9 | 0 up, 0 down | May 12, 2022 | $313.80M |
| Dec 31, 2021 | -$0.11 | -$0.13 | -$0.20 - $0.04 | +15.38% | Beat | -210.0% | 7 | N/A | Mar 22, 2022 | $275.33M |
| Sep 30, 2021 | -$0.10 | -$0.15 | -$0.15 - $0.05 | +33.33% | Beat | N/A | 7 | N/A | Nov 8, 2021 | $251.52M |
| Jun 30, 2021 | -$1.68 | -$1.55 | N/A | -8.39% | Miss | N/A | 5 | N/A | Aug 9, 2021 | $225.76M |
| Mar 31, 2021 | $0.06 | $0.04 | N/A | +50.00% | Beat | N/A | N/A | N/A | Apr 30, 2021 | $213.61M |
| Dec 31, 2020 | $0.10 | $0.08 | N/A | +25.00% | Beat | N/A | N/A | N/A | Mar 3, 2021 | $213.70M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.60, down 23.1% from the year before. It was $0.10 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.60 | -23.1% |
| Dec 31, 2024 | $0.78 | +50.0% |
| Dec 31, 2023 | $0.52 | N/A |
| Dec 31, 2022 | $0.52 | N/A |
| Dec 31, 2021 | -$1.83 | -1930.0% |
| Dec 31, 2020 | $0.10 | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,900 words across 19 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 7,941 | 19 | |
| 2026Q2 | Jun 30, 2026 | 5,924 | 20 | |
| 2026Q1 | Mar 31, 2026 | 8,231 | 21 | |
| 2025Q4 | Dec 31, 2025 | 8,845 | 23 | |
| 2025Q3 | Sep 30, 2025 | 6,476 | 21 | |
| 2025Q2 | Jun 30, 2025 | 8,017 | 22 | |
| 2025Q1 | Mar 31, 2025 | 8,597 | 24 | |
| 2024Q4 | Dec 31, 2024 | 7,188 | 25 |
2026Q3 Earnings Call
Opening remarks
Robert Borchert SVP of Investor and Corporate Communications Thank you, Elliot, and good morning, everyone. Joining me are CEO Parth Mehrotra and David Mountcastle, our Chief Financial Officer. This call is being webcast and can be accessed in the investor relations section of priviahealth.com, along with today's press release and slide presentation. Following our prepared comments, we will open the line for questions. Please limit yourself to one question only and return to the queue if you have a follow-up, so we can get to as many questions as possible. Today's reported results are preliminary and are not final until our Form 10-Q for the third quarter and nine-month period ended September 30, 2026, is filed with the Securities and Exchange Commission. Some of our statements today may be forward-looking in nature based on our current expectations and view of our business as of November 5th, 2026. Statements such as those related to our future financial and operating performance and future business plans and objectives are subject to risks and uncertainties that may cause actual results to differ materially. These statements should be considered along with our cautionary statements in today's press release and the risk factors described in our most recent SEC filings. Finally, we may refer to certain non-GAAP financial measures on the call, and reconciliations of these measures to comparable GAAP measures are included in our press release and the accompanying slide presentation posted on our website. Now I'd like to hand the call over to our CEO, Parth Mehrotra.
Parth Mehrotra CEO Thank you, Robert, and good morning, everyone. Today, I'll summarize our performance, market presence, and growth strategy, and David will discuss our financial results and updated 2026 guidance before we take your questions. Privia Health continues to demonstrate strong momentum and operational excellence across all aspects of our business. We delivered robust new provider signings, giving us clear visibility into our implementation pipeline for the remainder of 2026 and into 2027. Implemented providers grew 12.2%, and value-based attributed lives increased 19.2% compared to the first nine months of 2025. This drove year-to-date practice collections growth of 12% and adjusted EBITDA growth of 21.9%. EBITDA margin as a percentage of care margin increased to 28.8% as we continue to scale our operating cost structure. Given our strong year-to-date results, we are raising our 2026 outlook above the high end of our initial guidance for all key financial metrics. Implemented providers are now expected to be at the high end of our initial guidance. We expect to reach 6,000 clinicians by year-end, which is 11.5% growth over 2025. The midpoint of our adjusted EBITDA guidance is now above the high end of our initial guide and represents 23.9% growth over last year.
Frequently Asked Questions About PRVA
When is Privia Health Group's next earnings date?
Privia Health Group's next earnings report is expected for Feb 24, 2027.
Did PRVA beat earnings estimates last quarter?
Yes. Privia Health Group reported EPS of $0.10 for the quarter ended Sep 30, 2026, above the $0.09 estimate, a 11.11% surprise.
What EPS do analysts expect from PRVA next quarter?
The consensus EPS estimate for Privia Health Group for the quarter ending Dec 31, 2026 is $0.12 from 20 analysts, with estimates from $0.09 to $0.16.
How often does PRVA beat earnings estimates?
Privia Health Group beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +6.03%.
PRVA pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors